The RAGE/multiligand axis: A new actor in tumor biology
Por:
Rojas A., Schneider I., Lindner C., Gonzalez I., Morales M.A.
Publicada:
1 ene 2022
Resumen:
The receptor for advanced glycation end-products (RAGE) is a multiligand binding and single-pass transmembrane protein which actively participates in several chronic inflammation-related diseases. RAGE, in addition to AGEs, has a wide repertoire of ligands, including several damage-associated molecular pattern molecules or alarmins such as HMGB1 and members of the S100 family proteins. Over the last years, a large and compelling body of evidence has revealed the active participation of the RAGE axis in tumor biology based on its active involvement in several crucial mechanisms involved in tumor growth, immune evasion, dissemination, as well as by sculpturing of the tumor microenvironment as a tumor-supportive niche. In the present review, we will detail the consequences of the RAGE axis activation to fuel essential mechanisms to guarantee tumor growth and spreading. © 2022 The Author(s).
Filiaciones:
Rojas A.:
Biomedical Research Labs., Universidad Catolica Del Maule, Facultad de Medicina, 3605 San Miguel Ave., Talca, Chile
Schneider I.:
Biomedical Research Labs., Universidad Catolica Del Maule, Facultad de Medicina, 3605 San Miguel Ave., Talca, Chile
Lindner C.:
Biomedical Research Labs., Universidad Catolica Del Maule, Facultad de Medicina, 3605 San Miguel Ave., Talca, Chile
Gonzalez I.:
Biomedical Research Labs., Universidad Catolica Del Maule, Facultad de Medicina, 3605 San Miguel Ave., Talca, Chile
Morales M.A.:
Department of Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Universidad de Chile, Santiago, Chile, Santiago, 8320000, Chile
Gold
|